Cipla respiratory plan begins with albuterol

 
• By Dean Rudge

Cipla is targeting “one sizeable respiratory inhalation launch in the US every year”, starting with albuterol in the firm’s next financial year ending March 2020, as part of ambitions to become a significant respiratory player in regulated markets.

Cipla is targeting “one sizeable respiratory inhalation launch in the US every year”, starting with albuterol in the firm’s next financial year ending March 2020, as part of ambitions to become a significant respiratory player in regulated markets.

Market entry for albuterol could be as early as the fourth quarter of Cipla’s 2019 financial year, but ultimately “we don’t want to guide for that”, Umang Vohra, Cipla’s managing director and global chief executive officer, told investors as the firm

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Generics Bulletin, or if you love it how it is, now is the time to have your voice heard.

Is Towa’s Guidance For 2024 ‘Somewhat Mediocre?’

 
• By Dean Rudge

Bringing in sales that translated to nearly $1.5bn last year, Japan’s Towa was feeling upbeat after a challenging few years, both for itself and the broader Japanese generics market. However, its financial guide for the next 12 months has left investors feeling cold.

Publisher’s Spotlight: Citeline News And Insights App

 
• By Generics Bulletin Team

Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.

More from Generics Bulletin